Literature DB >> 31932337

Incidental lymphopenia and mortality: a prospective cohort study.

Marie Warny1, Jens Helby1, Børge Grønne Nordestgaard1, Henrik Birgens1, Stig Egil Bojesen2.   

Abstract

BACKGROUND: It is unknown if incidental lymphopenia detected in the general population is associated with higher all-cause and cause-specific mortality. We aimed to identify the associations between lymphopenia and all-cause and cause specific mortality.
METHODS: In a prospective cohort study, we examined and followed participants enrolled in the Copenhagen General Population Study between November 2003 and April 2015. In our analysis, we modelled risks using Cox proportional hazards regression for 3 groups: participants with a lymphocyte count below the 2.5th percentile; those with a lymphocyte count at or between the 2.5th and 97.5th percentiles (reference category); and those with a lymphocyte count above the 97.5th percentile.
RESULTS: The cohort included 108 135 participants with a median age of 68 years. During a median follow-up of 9 (interquartile range [IQR] 0-14) years, 10 372 participants died. We found that participants with lymphopenia (lymphocyte count < 1.1 × 109/L) compared with those with a lymphocyte count in the reference range (1.1-3.7 × 109/L) had higher mortality with multivariable adjusted hazard ratios (HRs) of 1.63 (95% confidence interval [CI] 1.51-1.76) for all causes, 1.67 (95% CI 1.42-1.97) for nonhematologic cancers, 2.79 (95% CI 1.82-4.28) for hematologic cancers, 1.88 (95% CI 1.61-2.20) for cardiovascular diseases, 1.88 (95% CI 1.55-2.29) for respiratory diseases, 1.86 (95% CI 1.53-2.25) for infectious diseases, and 1.50 (95% CI 1.19-1.88) for other causes. For all-cause mortality, the highest absolute 2-year risks of death were observed in women (61%) and men (75%) who smoked and were aged 80 years or older with lymphocyte counts less than 0.5 × 109/L. Participants with a lymphocyte count higher than the reference category had increased mortality (adjusted HR 1.17, 95% CI 1.04-1.31).
INTERPRETATION: We found that lymphopenia was associated with an increased risk of all-cause and cause-specific mortality.
© 2020 Joule Inc. or its licensors.

Entities:  

Mesh:

Year:  2020        PMID: 31932337     DOI: 10.1503/cmaj.191024

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  9 in total

Review 1.  Inflammatory biomarkers in older adults with frailty: a systematic review and meta-analysis of cross-sectional studies.

Authors:  YuShuang Xu; MengMeng Wang; Di Chen; Xin Jiang; ZhiFan Xiong
Journal:  Aging Clin Exp Res       Date:  2022-01-04       Impact factor: 4.481

2.  Prognostic Value of Pretreated Blood Inflammatory Markers in Patients with Bone Sarcoma: A Meta-Analysis.

Authors:  Min Jiang; Shaowei Ma; Zhongyan Hua; Zhiying Zhao; Song Gao
Journal:  Dis Markers       Date:  2021-04-08       Impact factor: 3.434

3.  The Independent Association of TSH and Free Triiodothyronine Levels With Lymphocyte Counts Among COVID-19 Patients.

Authors:  David Tak Wai Lui; Chi Ho Lee; Wing Sun Chow; Alan Chun Hong Lee; Anthony Raymond Tam; Polly Pang; Tip Yin Ho; Chloe Yu Yan Cheung; Carol Ho Yi Fong; Chun Yiu Law; Kelvin Kai Wang To; Ching Wan Lam; Kathryn Choon Beng Tan; Yu Cho Woo; Ivan Fan Ngai Hung; Karen Siu Ling Lam
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-13       Impact factor: 5.555

4.  Pre-Existing Lymphopenia Increases the Risk of Hospitalization and Death after SARS-CoV-2 Infection.

Authors:  Riccardo Garbo; Francesca Valent; Gian Luigi Gigli; Mariarosaria Valente
Journal:  Infect Dis Rep       Date:  2022-01-04

5.  Lymphopenia and mortality among patients undergoing coronary angiography: Long-term follow-up study.

Authors:  Barak Zafrir; Sliman Hussein; Ronen Jaffe; Ofra Barnett-Griness; Walid Saliba
Journal:  Cardiol J       Date:  2020-11-03       Impact factor: 3.487

6.  Neutrophil to lymphocyte ratio is not related to carotid atherosclerosis progression and cardiovascular events in the primary prevention of cardiovascular disease: Results from the IMPROVE study.

Authors:  Massimo R Mannarino; Vanessa Bianconi; Bruna Gigante; Rona J Strawbridge; Kai Savonen; Sudhir Kurl; Philippe Giral; Andries Smit; Per Eriksson; Elena Tremoli; Fabrizio Veglia; Damiano Baldassarre; Matteo Pirro
Journal:  Biofactors       Date:  2021-11-11       Impact factor: 6.438

7.  Lymphopenia and Mechanisms of T-Cell Regeneration.

Authors:  E V Saidakova
Journal:  Cell tissue biol       Date:  2022-08-08

8.  Importance of hematological parameters for micro- and macrovascular outcomes in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study.

Authors:  Claudia R L Cardoso; Nathalie C Leite; Gil F Salles
Journal:  Cardiovasc Diabetol       Date:  2021-07-06       Impact factor: 9.951

9.  Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality.

Authors:  Juan Carlos Andreu-Ballester; Aurelio Pons-Castillo; Antonio González-Sánchez; Antonio Llombart-Cussac; María José Cano; Carmen Cuéllar
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.